[144] OCULAR THERAPEUTIX, INC SEC Filing

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. filed a Form 144 reporting a proposed sale of 11,132 common shares valued at $137,400.05, with an approximate sale date of 10/08/2025 on NASDAQ. The shares were acquired on 10/07/2025 through restricted stock vesting under a registered plan, and payment (if any) was recorded as Not Applicable. The filing lists 173,995,221 shares outstanding for the issuer. No sales by the reporting person in the prior three months are reported. The filer affirms they are not aware of undisclosed material adverse information and includes broker details for Morgan Stanley Smith Barney LLC.

Positive

• Sale follows documented restricted stock vesting with acquisition dated 10/07/2025
• Broker identified as Morgan Stanley Smith Barney LLC for the planned execution
• No sales in the prior three months are reported for the selling person

Negative

• None.

Insights

Securities Compliance Officer

TL;DR: This is a routine Rule 144 notice tied to restricted stock vesting with brokered sale planned.

The filing documents a proposed Rule 144 sale of 11,132 vested shares, recorded with Morgan Stanley Smith Barney LLC and an intended execution date of 10/08/2025. The acquisition date is listed as 10/07/2025 and the notice includes the standard attestation about undisclosed material information.

Key procedural dependencies are confirmation of transferability under Rule 144 and timely public disclosure of any material issuer events prior to sale. Watch execution timing and whether any subsequent filings amend the quantity or timing within days of 10/08/2025.

Equity Transactions Analyst

TL;DR: The notice records a single small sale following restricted vesting; no prior three‑month sales reported.

The notice states the shares were issued via restricted stock vesting under a registered plan on 10/07/2025 and the seller plans to offer them through a named broker on 10/08/2025. The filing lists the issuer's outstanding shares as 173,995,221, providing context for the scope of this transaction.

Investor‑relevant items to observe are any follow‑on Form 4 or Form 144 amendments around 10/08/2025 that report execution, and whether multiple insiders file similar notices in the same window.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11132	137400.05	173995221	10/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/07/2025	Restricted stock vesting under a registered plan	Issuer			11132	10/07/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does OCUL's Form 144 report?

It reports a proposed sale of 11,132 common shares valued at $137,400.05 with an approximate sale date of 10/08/2025.

How were the shares acquired according to the filing?

The shares were acquired on 10/07/2025 through restricted stock vesting under a registered plan.

Which broker is handling the planned sale for OCUL?

The broker named is Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, NY.

Does the filing show prior sales by the same person in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

What outstanding share count does the filing list?

The filing lists 173,995,221 shares outstanding for the issuer.